Why the study?
Does Torque teno virus (TTV) load predict clinical events and efficacy of immunosuppression in lung transplant recipients?
Does Torque teno virus (TTV) load predict clinical events and efficacy of immunosuppression in lung transplant recipients?
Answers are grounded in this paper and cite their sources.
TTV-load predicts clinical events such as severe infections and chronic lung allograft dysfunction, suggesting its potential utility in optimizing immunosuppression after lung transplantation.
Torque teno viruses (TTV) are small DNA-viruses, of the genus Alphatorquevirus, whose replication is linked to immune status. TTV load may be an indicator for efficacy of IS in lung transplant recipients (LTRs). In a prospective single-center-study 143 LTRs were followed up and tested by quantitative TTV-DNA PCR. Using multivariate Cox-regression contribution of TTV-load to the occurrence of severe infections, chronic lung allograft dysfunction (CLAD), acute cellular rejection (ACR), and death was assessed. During follow-up 28 (20%) patients developed infections with a rate of 7.7 per 100 patient-years (PY). The hazard-ratio (HR) associated with a one-log10 increase of TTV-load before the event was 5.05. CLAD occurred with a rate of 6.0%-PY. HR for a 1 log10 increase of the lowest TTV level before the event was 0.71 (CI: 0.54-0.93). TTV-load predicts clinical events and may be useful to optimize IS during the first years of follow-up of LTRs.
No takes yet. Share an insight, caveat, or question.
Jaksch et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: